feedback

Course Director

Stewart J. Tepper, MD, FAHS
Stewart J. Tepper, MD, FAHS

Geisel School of Medicine at Dartmouth
Hanover, New Hampshire

Faculty

Lawrence C. Newman
Lawrence C. Newman, MD

NYU Langone Health
Preston Robert Tisch Center for Men’s Health
New York, New York

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.25 Credits
Release Date:2018-Dec-03
Expiration Date:2019-Dec-02
Estimated Time for Completion:75 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years the evidence on the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has been consolidated, and new and promising treatments for prevention have been developed. The monoclonal antibody directed against the CGRP receptor, erenumab-aooe, is one example of an agent now approved for migraine prevention in adults. Several antibodies directed against the CGRP ligand (fremanezumab, galcanezumab, and eptinezumab) have shown to be effective in the prevention of episodic and chronic migraine. In this activity, based on a recent live symposium held in Atlanta, Georgia, at the 143rd Annual Meeting of the American Neurological Association, experts in the management of this neurologic disorder discuss pathways that are common to episodic and chronic migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice.

Upon completion of this activity, participants should be better able to:
  • Identify the benefits and potential disadvantages of conventional preventive therapies for the management of migraines
  • Describe the pathophysiologic pathways that are common to episodic and chronic migraines
  • Assess current evidence related to newly available and emerging therapies for headache prevention in patients with episodic or chronic migraines
  • Recognize the potential impact of new and emerging preventive therapies on the current and future management of patients with migraines
  • Apply strategies to personalize preventive management in individuals with migraines

Target Audience

This activity has been designed to meet the educational needs of neurologists and other clinicians involved in the care of patients with migraines.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 03, 2018 - December 02, 2019
Time to Complete: 75 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Stewart J. Tepper, MD, FAHS
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire

Stewart J. Tepper, MD, FAHS, has a financial interest/relationship or affiliation in the form of:
Consultant for Acorda Therapeutics; Alder BioPharmaceuticals, Inc.; Allergan; Amgen Inc.; Alexza; AlphaSights Ltd.; ATI; Axsome Therapeutics, Inc.; Charleston Laboratories, Inc.; DeepBench; Dr. Reddy’s Laboratories Ltd.; electroCore, Inc.; Eli Lilly and Company; eNeura Inc.; GLG Pharma, Inc.; Guidepoint Global, LLC; Magellan Health, Inc.; Neurolief Ltd.; Nordic Biotech; Scion NeuroStim LLC; Slingshot Insights; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; and Zosano Pharma Corporation.
Shareholder in ATI.

Stewart J. Tepper, MD, FAHS, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Investigational therapies for migraine.

Faculty

Lawrence C. Newman, MD
Director, Headache Division
Clinical Professor of Neurology
NYU Langone Health
Preston Robert Tisch Center for Men’s Health
New York, New York

Lawrence C. Newman, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.
Advisory Board for Alder BioPharmaceuticals, Inc.; Allergan; Eli Lilly and Company; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceuticals USA, Inc.

Lawrence C. Newman, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Investigational therapies for migraine.

CME Reviewer

Randy Rosenberg, MD, FAAN, FACP

Randy Rosenberg, MD, FAAN, FACP, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kirk Tacka, PhD
PVI, PeerView Institute for Medical Education

Kirk Tacka, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational funding provided by Alder BioPharmaceuticals, Amgen, and Teva Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.